For immediate release |
8 October 2010 |
Futura Medical plc
("Futura" or "the Company")
Issuance of Shares Following Employee Option Exercise
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, has applied for 160,000 new ordinary shares of 0.2p each in the Company to be admitted to trading on AIM. The shares are being issued following the exercise of options.
The shares will rank pari passu with existing ordinary shares and dealings are expected to commence in the new ordinary shares at 8.00am on 12 October 2010. Pursuant to AIM Rules, the Company's total issued share capital following the anticipated admission of the shares as set out above is 67,643,311.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.com |
|
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / George Prassas |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.